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A B S T R A C T
Purpose
Historically, African American women have experienced higher breast cancer mortality than white
women, despite lower incidence. Our objective was to evaluate whether costs of increasing rates
of screening or application of intensive treatment will be off-set by survival benefits for African
American women.
Methods
We use a stochastic simulation model of the natural history of breast cancer to evaluate the incremental
societal costs and benefits of status quo versus targeted biennial screening or treatment improvements
among African Americans 40 years of age and older. Main outcome measures were number of
mammograms, stage, all-cause mortality, and discounted costs per life year saved (LYS).
Results
At the current screening rate of 76%, there is little incremental benefit associated with further increasing
screening, and the costs are high: $124,053 and $124,217 per LYS for lay health worker and patient
reminder interventions, respectively, compared with the status quo. Using reminders would cost
$51,537 per LYS if targeted to virtually unscreened women or $78,130 per LYS if targeted to women
with a two-fold increase in baseline risk. If all patients received the most intensive treatment
recommended, costs increase but deaths decrease, for a cost of $52,678 per LYS. Investments of up
to $6,000 per breast cancer patient could be used to enhance treatment and still yield cost-effectiveness
ratios of less than $75,000 per LYS.
Conclusion
Except in pockets of unscreened or high-risk women, further investments in interventions to increase
screening are unlikely to be an efficient use of resources. Ensuring that African American women receive
intensive treatment seems to be the most cost-effective approach to decreasing the disproportionate
mortality experienced by this population.
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INTRODUCTION
Breast cancer is second only to lung cancer
as the leading cause of potentially avoidable
cancer mortality among women.1,2 In the
last two decades, the mortality rate from
breast cancer has decreased by approxi-
mately 7% in younger white women.1 How-
ever, African American women have yet to
realize similar mortality reductions, and
older African American women have expe-
rienced an increase in mortality, despite a
lower incidence of disease than their white
counterparts.1,3 A portion of the excess
mortality seen in African American women
could be caused by low rates of screening,
failure to receive timely and complete diag-
nostic follow-up, or receiving suboptimal
treatment. For instance, historically, African
American women had significantly lower
rates of mammography screening4-6 and
later-stage diagnosis7-12 than did white
women. Although disparities in screening
rates have significantly diminished in recent
years,13some, such as poor, minority, and
older women, still remain at risk for having
their cancers detected at later stages.7 Once
African American women are screened, if
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they have cancer, treatment is often suboptimal.3,14-16
Thus, there are important points in the process of breast
cancer control where interventions could potentially reduce
the disproportionate morbidity and mortality observed in
African American women.
Prior cost-effectiveness analyses of breast cancer
screening have demonstrated that reductions in mortality
can be achieved at a reasonable cost per life year saved in
general17-21 as well as in selected groups of older22-25 and/or
older African American women.25 However, there are no
data regarding whether additional expenditures to enhance
the cancer control process for African American women
would result in improved overall survival at reasonable
societal expenditures.
In this study, we use a model simulating the natural
history of breast cancer to test the hypothesis that the added
costs of targeted programs to increase screening or enhance
receipt of intensive systemic treatment will be off-set by the
downstream benefits of increased survival among African
American women who develop breast cancer.
METHODS
We used an event-driven, continuous-time Monte Carlo simula-
tion model to evaluate the costs, harms, and benefits of adding new
cancer control interventions to current United States patterns of
care for African American women. We compared targeted clinical
screening interventions (patient reminders or lay health worker)
versus status quo biennial screening or receiving optimal treat-
ment (consistent with current recommendations) versus current
patterns of care. We calculated incremental cost-effectiveness ra-
tios, where the additional costs of a strategy, divided by the added
savings in life years, are compared with the next least expensive
effective strategy.26 We also calculated intermediate outcomes,
including number of abnormal mammograms, number of false-
positives, number of cancers diagnosed, and stage distribution
associated with each strategy. All costs and effects are discounted at
3%.26 All scenarios were examined by generating 1.25 million
simulated patients, a sample size chosen to ensure that the SE of
the estimated population life expectancy would be less than 2 days.
We used a matched simulation approach to maximize computer
resource efficiency and maximize the precision of our effect esti-
mates.27 Briefly, in the analyses of screening interventions as an
example, each simulated woman is simulated twice: once with
screening and the other time without. The random numbers used
for all variables simulated for the woman are identical in the two
simulations (matched), except for the fact of screening and the
events after screening. The comparison between intervention sce-
narios was then made by varying the proportion of simulated
women who are screened versus unscreened in the given scenario.
Disease Natural History Model
We developed Monte Carlo simulations28 to portray the
dynamic processes of breast cancer incidence, detection, progres-
sion, and treatment (Fig 1). The model begins with a hypothetical
cohort of 40-year-old African American women and randomly
assigns dates of death, symptomatic breast cancer incidence, and
date of first and subsequent biennial screening mammograms. For
instance, women who are destined to get breast cancer are assigned
a date at which symptomatic illness will present. The stage of
symptomatic presentation is selected randomly from age-specific
distributions in unscreened women. If women are screened and
the tumor is detected before this time (a true-positive screen), a
new stage is calculated using Bayes’ theorem with a prior distribu-
tion taken from screened breast cancer incidence rates and a
conditional distribution calculated from the rates of transition
through the stages (ductal carcinoma-in-situ [DCIS], local, re-
gional, and distant) and the simulated lead time. Women who are
screened but do not have their tumor detected (false-negative)
return to routine screening; their tumor may be detected on sub-
sequent screening rounds or they may present with symptomatic
disease. When women develop breast cancer, they are also ran-
domly assigned an estrogen receptor (ER) status based on their age
and race (African American or not). Treatment is randomly se-
lected based on current patterns of care, given age, African Amer-
ican race, stage at presentation, and ER status. Recurrence and
survival probabilities are assigned based on this selection.
For women who do not develop cancer, the probability of a
false-positive mammogram is based on the general age-specific
specificity of mammogram and the number of mammograms
received between age 40 years and the date of death. Finally,
interventions designed to improve screening use and rates of re-
ceipt of intensive treatment modify events in the model (eg, in-
crease probability of screen detection, increase survival through
use of chemotherapy to treat ER-negative disease). We chose a
biennial screening interval because this is the standard tested in
randomized trials and the interval used in most prior cost-
effectiveness analyses of breast screening.
Model Assumptions
There are several underlying assumptions in our model (Ta-
ble 1). The key assumption is that the differences in distribution of
ER status by race represent a proxy for general race-specific differ-
ences in tumor markers. Although biologic factors seem to only
account for a small proportion of the variance in survival between
African American and white women,29,30 African American
women are significantly more likely to have ER-negative tumors
than white women,31 and stage for stage, women with ER-negative
tumors have shorter disease-free and overall survival than women
with ER-positive tumors.30,32-34 Although other markers of bio-
logic variability, such as tumor differentiation,35 S-phase frac-
tions,30 and new genetic biomarkers (eg, erb-b-2),35,36 also affect
survival and may vary by race, there are presently insufficient
race-specific treatment and survival data by these markers to in-
clude in our model.
Second, at this time there are insufficient good-quality ER-
stratified survival data for DCIS, so we assume that all women
diagnosed with carcinoma-in-situ will have overall age-specific
DCIS survival. We also make the simplifying assumption that
lobular carcinoma-in-situ and DCIS have the same natural history
and survival.
Next, although there are good-quality data for the short-term
effects of the screening interventions we evaluate, there are little
data available to describe their long-term effects. Although there is
some evidence that effectiveness declines over time to baseline,37
we model the interventions as having an enduring effect on the
relative risk of remaining unscreened (favors enhanced screen-
ing). Fourth, because the age-, ER-, and treatment-stratified sur-
vival we used were based on up to 15 years of observation, we made
several simplifying assumptions about average survival beyond
this period. We assumed that women either diagnosed with DCIS
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destined to progress to local stage-invasive disease or those diag-
nosed with local stage who survived for 15 years without recur-
rence would have similar survival after that time as their age- and
race-matched non– breast cancer cohort (eg, are cured). Survival
for women with DCIS and local disease who have recurrent
disease at 15 years, or for women with regional disease surviv-
ing 15 years, was estimated using stage-specific declining expo-
nential approximation of life expectancy.38 We also assume
that survival is the same for women with screen-detected and
clinically detected cancers. This assumption is likely to under-
estimate the effectiveness of mammography.
Finally, in our model, the effectiveness of mammography is
represented purely by the resulting stage shift. We use the stage
distributions of tumors observed in a period before mammogra-
phy (1975 to 1979) and in the current period (1995 to 2001) when
use was high to represent the stage distributions of clinically de-
tected and screen-detected lesions, respectively.
Model Parameters
To estimate the probability of all costs and events in the
model, we reviewed the literature for population-based studies
applicable to African Americans. If race-specific data were not
available, we used data from the general population. Parameters
are listed in Tables 2 and 3.
Disease Natural History
Breast cancer incidence rates for African American women
were estimated from Surveillance, Epidemiology, and End Results
(SEER) data.1 Stage distributions for screened and unscreened
women were taken from two different sources. Data from SEER
from 1975 to 1979 were used to approximate the distribution of
events in the absence of screening.1 Data from the Breast Cancer
Surveillance Consortium39 from 1995 to 2001 were used to repre-
sent the stage distribution for screen-detected African American
women (Breast Cancer Surveillance Consortium, W. Barlow, per-
Fig 1. Model structure for evaluating
the benefits and costs of breast
cancer–control intervention to improve
outcomes in African Americans. Flow
of events processed in the simulation
of the natural history of breast cancer
is shown. Some events incur costs or
quality-of-life reductions. At the end
of the simulation, events are tallied,
and costs and quality adjustments
are applied.
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sonal communication, June 2002). Screen-detected cancer was
defined as a cancer diagnosed within 3 months of a positive screen-
ing mammogram performed in the absence of symptoms; screen-
ing intervals reflected average population use. Because women
who were reported as having stage unknown in SEER1 in both
periods had survival rates between those of women with regional
and distant disease. Therefore, among the 10% of women with
missing stage for each period, we reassigned 50% as regional and
50% as distant.
Time to stage progression (eg, from DCIS to invasive cancer,
from local to regional disease, or from no active disease to recur-
rence) was estimated based on data from randomized clinical trials
of breast cancer screening and simulating stage distributions in the
screened and unscreened settings.40-44 Average dwell times were
assumed to have an exponential distribution.43,44
Test Characteristics
We used age-specific test characteristics45 for all races of
women, because the health-insurance plan trial demonstrated
similar effects of mammography on mortality for African Ameri-
can and white women.40 We use different values for the sensitivity
and specificity of the first versus subsequent mammogram, be-
cause the first screen detects more prevalent than incident disease.
Prevalent tumors are, on average, larger than incident tumors, and
potentially easier to detect than new tumors.45
Rates of Mammography Use
Current rates of recent mammography use are, on average,
quite high (76%).4 Because average rates may mask pockets of
underscreening, we tested the cost-effectiveness of enhanced
screening interventions across a range of baseline screening rates
in sensitivity analyses.
Interventions to Improve Mammography Use
We evaluated the effects (and costs, discussed further herein)
of patient reminder letters46-48 and outreach by lay health
workers49-53 to increase use of initial and subsequent screening.
We also considered but did not include other interventions, in-
cluding church-based workers, theory-based educational counsel-
ing telephone calls, scheduling of mammography the same day as
the medical referral visit, and physician reminders or audit with
feedback to prompt physicians to order screening.79,80 These latter
interventions were not included because they were of similar or
lesser effectiveness and/or were more costly than patient remind-
ers and lay workers.
To estimate the effect of patient reminders and lay health
workers, we combined data from studies in random-effects meta-
analysis models to calculate the relative risk of remaining un-
screened after the one-time application of the intervention.
Diagnostic Evaluation
We assumed that women with an abnormal mammogram
undergo diagnostic evaluation; women who have breast cancer
also have a staging evaluation.
Treatment
Current patterns of age-, race-, and stage-specific local surgi-
cal therapy were estimated from SEER public use files.1 We assumed
that initial decisions about use of mastectomy, breast conservation,
and radiation are independent of ER status. Age- and race-specific
patterns of adjuvant treatment were estimated from published data.54
These latter data are not available by ER status.
Improving Treatment Patterns
Rates of use of adjuvant therapies are below those advocated
by professional groups.55,56 We assessed the effectiveness of pro-
viding all women with the most intensive indicated adjuvant ther-
apy, defined as all women with ER-negative invasive tumors
receiving multiagent chemotherapy and all women with ER-
positive invasive tumors receiving both multiagent chemotherapy
and tamoxifen. Because we are not aware of any interventions to
increase use of chemotherapy, we calculated a cost threshold.
Life Expectancy
The probability of dying within each 1-year age interval be-
ginning at age 40 years was abstracted from life tables for African
American women compiled by the National Center for Health
Statistics.81 For women with breast cancer, we used pooled data
from thirteen National Surgical Adjuvant Breast and Bowel
Project treatment trials evaluating surgery, radiotherapy, hor-
monal therapy, and chemotherapy treatments among approxi-
mately 20,000 women to estimate relapse-free and overall survival
up to 15 years by stage, treatment, age ( 40 years; 40 to 49 years;
50 to 59 years; 60 years), and ER status.57-69
Costs
We included medical care (consumable supplies, personnel,
laboratory, and procedure costs) and nonmedical care (patient
time costs) direct costs (Table 3). All costs are converted to year
2000 United States dollars using the medical care component of
the consumer price index for the year of data collection.82 The cost
of routine screening mammography was based on an extended
office visit to discuss mammography plus the costs of a mammo-
gram.70,71 Costs of an evaluation of a false-positive abnormal
mammogram were estimated to be $93.35.72 The costs of cancer
diagnosis, treatment, continuing, and terminal care were esti-
mated from linked SEER-Medicare reimbursement data from
1990 to 1999 using the method described by Warren et al73 and
Brown et al.83 These phase-specific data do not specify the costs for
specific therapies; rather, they provide an average of the costs of all
regimens actually consumed by women in the period of obser-
vation. We assume that Medicare reimbursements, which are
based on the Medicare Resource-Based Relative Value Scale,
closely approximate societal costs.84 Because Medicare does
not cover the costs of tamoxifen, we added the wholesale costs
of tamoxifen for women receiving this treatment.77 The costs of
optimal treatment were based on Medicare costs plus the added
costs of tamoxifen and chemotherapy; chemotherapy costs
were based on wholesale costs.77 Because some chemotherapy
Table 1. Model Assumptions
Disease biology
ER status is a proxy for race differences in biology of invasive
cancer
Lobular and ductal in-situ cancers have the same survival
Survival after 15 years
DCIS and local  general population
Regional or recurrent disease  DEALE
Screen-detected and clinically detected cancers have the same
survival
Screening
Intervention effects persist over the long term
Abbreviations: ER, estrogen receptor; DCIS, ductal carcinoma-in-situ;
DEALE, declining exponential approximation of life expectancy.
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Table 2. Natural History of Disease Parameters in African American Women
Parameter
Estimate (%)
Reference No.In-Situ Local Regional Distant
Stage distribution for screen-detected breast cancers 1995-2001 for African American women* by age, years
40-44 16.0 32.0 41.5 9.5 Breast Cancer Surveillance
45-49 25.0 38.0 31.5 6.5 Consortium, personal
50-54 18.0 48.0 22.5 12.5 communication, June
55-59 7.0 66.0 17.5 9.5 2002; 39
60-64 12.0 51.0 26.0 11.0
65-69 17.0 46.0 24.5 12.5
70-74 17.0 40.0 25.0 18.0
75-79 19.0 44.0 23.5 12.5
80-84 14.0 64.0 13.5 9.5
85 25.0 75.0 0 0
Stage distribution for non–screened-detected breast cancer cases 1975-1979 for African American women* by age, years 1
40-44 3.8 38.0 48.4 9.8
45-49 6.5 39.3 43.7 10.5
50-54 3.4 37.5 47.7 11.4
55-59 3.5 39.9 45.0 11.6
60-64 3.3 38.3 44.2 14.2
65-69 3.9 36.6 46.2 13.3
70-74 5.8 36.4 38.4 19.4
75-79 5.2 39.9 39.3 15.6
80-84 0 28.6 45.9 25.5
85 2.5 33.3 45.1 19.1
Mean 95% CI RR† SD Reference No.
Estrogen receptor positivity for African American women by age in years, % 31
35-49 48 42.8 to 53.2
50-64 66 61.1 to 70.9
65-79 76 71.5 to 81.5




























Mammography use, African American women having reported mammogram in past 2 years, % 13
Median 76.1
Range 44.3-85.5
Mammography use, relative risk of being
unscreened after patient reminder interventions
0.58 to 0.92 0.73 46-48
Relative risk of remaining unscreened
after exposure to lay health worker
intervention
0.75 to 0.89 0.82 49-53
(continued on following page)
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Distribution of local treatment for African American women diagnosed with breast cancer between 1993-1997 1
DCIS, years
40-44 42.2 35.8 22.0
45-49 45.2 31.9 22.9
50-54 45.4 29.8 24.8
55-59 35.8 35.0 29.2
60-64 35.9 29.7 34.4
65-69 41.9 30.2 27.9
70-74 35.7 32.2 32.2
75-79 42.7 18.3 39.0
80-84 47.8 21.7 30.4
85 81.0 4.8 14.3
Local, years
40-44 24.4 45.5 30.1
45-49 18.4 46.5 35.1
50-54 18.4 46.8 34.8
55-59 13.2 46.8 40.0
60-64 15.6 40.8 43.6
65-69 10.5 39.9 49.6
70-74 18.2 39.4 42.4
75-79 22.1 31.3 46.6
80-84 36.7 20.3 43.0
85 48.6 15.9 35.5
Regional, years
40-44 8.1 31.9 60.0
45-49 13.9 29.5 56.6
50-54 15.5 25.9 58.6
55-59 10.3 20.7 69.0
60-64 10.6 24.6 64.8
65-69 12.9 19.9 67.2
70-74 12.2 19.6 68.2
75-79 7.0 14.8 78.1
80-84 18.2 15.2 66.7
85 17.5 5.0 77.5
Distant
40-49 25.8 21.0 53.2
50-59 20.4 20.4 59.3
60-69 19.6 15.7 64.7
70 32.1 13.2 54.7
ER, ER (%)
Chemotherapy Tamoxifen Both Neither
Systemic treatment distribution by stage for African American women, 1995 54
DCIS, years
Age  50 0.0 16.0 0.0 84.0
Age 50-64 0.0 40.1 0.0 59.1
Age  65 0.0 48.7 0.0 52.3
Local, years
Age  50 34.1 16.6 11.0 38.4
Age 50-64 13.6 40.1 10.9 35.3
Age  65 2.0 48.7 0.3 49.0
Regional/distant, years
Age  50 53.8 2.9 32.4 11.0
Age 50-64 26.6 18.8 42.3 12.3
Age  65 11.4 45.0 23.4 20.2
ER ER Reference No.
Most aggressive treatment for all women 55,56
DCIS Tamoxifen —
Local Chemotherapy  tamoxifen Chemotherapy
Regional Chemotherapy  tamoxifen Chemotherapy
Distant Chemotherapy  tamoxifen Chemotherapy
5-year recurrence-free survival
probability for all women
See text 57-69
5-year survival probability for all women See text 57-69
Abbreviations: RR, relative risk; SD, standard deviation; DCIS, ductal carcinoma-in-situ; Loc, local; Reg, regional; Dist, distant; ER, estrogen receptor.
The 10% of unstaged women were distributed as follows: 50% regional and 50% distant based on survival.
†Random effects model estimate RR (unscreened).
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costs are already included in the Medicare costs, we overestimated
costs, which biases against interventions to enhance therapy.
Costs associated with the screening interventions were calcu-
lated using micro-costing methods. Nonmedical costs included
patient time spent receiving screening, diagnostic evaluation, and
treatment, and travel and waiting time for receiving care. Average
travel and waiting times and time spent receiving services were
estimated from prior research and clinical estimates.74-76 Costs
were obtained by multiplying these times by median United States
wage rates for African American women.82 The costs of lost pro-
ductivity as a result of breast cancer morbidity and mortality
would be accounted for by decrements in utilities used to quality-
adjust years of life saved (see next section).
Sensitivity Analyses
We varied individual parameters and combinations of
parameters over different ranges to examine the robustness of
the model results under a variety of conditions. We used life
years saved as our base model because utilities did not affect
conclusions. Quality-adjusted life years are examined in sensi-
Table 3. Costs of Breast Cancer Care (year 2000 costs)













Mammography visit 30.00 70,71
Total cost of evaluating abnormal
mammogram for all women
95.35 71,72
Average monthly treatment costs for African American women by phase and stage 72,73
Initial phase†
DCIS 448 89 2,073 186 1,646 177
Local 1,355 107 2,261 166 1,874 201
Regional 2,217 390 2,597 179 2,435 112
Distant 2,434 616 2,852 454 2,623 296
Continuing phase‡
DCIS 148 49 198 58 152 39
Local 241 43 156 29 210 22
Regional 289 116 166 47 212 28
Distant 394 201 573 208 196 117
Terminal phase§
DCIS 2,168 455 1,266 890 2,505 663
Local 3,283 400 2,583 365 3,318 833
Regional 2,469 472 3,204 338 2,731 271
Distant 3,146 693 3,173 425 2,785 519
Monthly patient time costs (travel, treatment) 74-76
Initial phase
All stages 26 91 61 39
Continuing phase
DCIS/local 5.08/year 5.08/year 5.08/year 5.08/year
Regional/distant 6.33/year 6.33/year 6.33/year 6.33/year
Terminal phase
All stages 10 10 10 10
Cost of tamoxifen over 5-year
period
6,352 77




screening for all women
(per patient) 74,75,78
Reminder letter 56
Lay health worker 63
Abbreviation: DCIS, ductal carcinoma-in-situ.
Year 2000 dollars.
†The initial phase of care includes all costs incurred by breast cancer patients for the 12-month period after the date of diagnosis (eg, initial evaluation,
hospitalizations, and surgery, and any adjuvant chemotherapy, medical visits, laboratory procedures).73
‡The continuing care phase includes all costs after the initial phase up to the 12 months period to death (eg, medical visits, hospitalizations, mammograms,
laboratory procedures, etc).73
§Terminal care costs refer to all costs in the last 12 months of life (eg, hospitalizations, chemotherapy, laboratory procedures, and medical visits).
73
Interventions were micro costed.
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tivity analyses (1.0, healthy, no cancer; 0.85, local; 0.7, regional;
0.5, distant).
Model Validation and Statistical Testing
Programming accuracy was verified using input designed to
test the model under hypothetical conditions in which the results
should be obvious. Our scientific advisors reviewed model face
and clinical validity.
Role of Funding Source
The funding agencies had no role in data analysis, interpre-
tation of results, or decisions to publish the results.
RESULTS
Screening
African American women have a 7.2% cumulative risk
of developing breast cancer from age 40 years to death in
our simulation. At status quo baseline screening rates of
76%, with a program of biennial screening beginning at age
40 years, each woman will undergo an average of 10 mam-
mograms in her lifetime and has a 54% cumulative risk of
having a false-positive screening result in this period (Table
4). Compared with no screening, screening saves 11 days of
life per capita (undiscounted).
Using patient reminders or lay workers increases the
average number of mammograms from the status quo by
less than one over a lifetime and increases the risk of a
false-positive screen by 6.5%. At current screening levels,
enhanced screening efforts are associated with only a slight
increase in population life expectancy after age 40 years
( 1 day per woman, undiscounted); there is only a mar-
ginal difference between the two approaches. Among
women destined to develop breast cancer, increasing
screening saves an additional 11 days of life compared with
the current status quo.
The incremental cost-effectiveness ratios associated with
increased screening resulting from patient reminders and lay
navigation are shown in Table 4. Comparing each approach to
the status quo, both result in cost-effectiveness ratios of greater
than $100,000 per life year saved. These high costs reflect
increased use of mammography and earlier expenditures on
treatment without appreciable benefits in life extension.
Treatment
Compared with current patterns of care, if all women
were to receive the most intensive systemic therapy, an
average of 0.053 years or 19.3 additional days would be
saved, spread out over the entire population (undis-
counted). These savings are attributable to the additional
savings of 266 days of life among the breast cancer patients.
If all women received the most intensive treatment recom-
mended in consensus guidelines compared with status quo
patterns, it would cost $52,678 per life year saved (Table 4).
Investments in interventions to enhance treatment adher-
ence to this level of up to $6,000 per breast cancer patient
would still yield cost-effectiveness ratios of less than $75,000
per year of life saved.
Sensitivity Analysis
If we assume maximal screening intervention effective-
ness of patient reminders and apply the intervention in
populations of women with the lower bound of current
screening rates (44%), the cost per life year saved remains
high: $98,447 compared with the status quo. However, in-
vestments in enhanced screening (eg, reminders) become
cost-effective in areas with pockets of unscreened or very
underscreened women (eg, $51,537 compared with no
screening). If screening is targeted to women with a two-
fold baseline increase in risk of developing breast cancer (eg,
a first-degree relative with breast cancer), then enhanced
screening using patient reminders has greater benefits than
in the general population, and results in a cost-effectiveness
ratio of $78,129 per life year saved compared with the status
quo situation.
















No screening — — 3,511.93 N/A 21.299179 N/A N/A
Status quo screening
and treatment
9.97 0.66 4,138.93 627.00 21.30649 0.007312 85,755/LY
Lay health worker
v status quo
10.53 0.70 4,238.18 99.24 21.307290 0.000800 124,053/LY
Patient reminder v
status quo
10.82 0.71 4,247.00 108.07 21.30736 0.000870 124,217/LY
Enhanced treatment
v status quo†
9.97 0.66 5,143.50 1004.57 21.32556 0.019070 52,678/LY
Abbreviations: N/A, not applicable; LY, life years.
Status quo is compared with no screening. Status quo treatment refers to patterns of care reported to Surveillance, Epidemiology and End Results.
1,54
†All women receive intensive therapy following consensus guidelines (surgery [and radiation after lumpectomy] plus adjuvant therapy, where all women with
local and regional disease who are estrogen receptor-negative receive chemotherapy; women who are estrogen receptor-positive receive tamoxifen and
chemotherapy).55,56
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Adjustment for a range of utility values does not change
the conclusion that enhanced screening is not cost-effective
at current screening levels (eg, using patient reminders v
status quo screening is also very expensive when utilities are
considered, costing $200,000 per quality-adjusted life
years). Delays in the timing of diagnostic evaluation of an
abnormal screening test decrease the cost-effectiveness ra-
tios for screening minimally, because delay would have to
lead to stage progression from one stage to the next to have
a significant impact on life expectancy (data not shown).
DISCUSSION
This is the first analysis that we are aware of that examines
the cost effectiveness of breast cancer screening in African
American women and examines the costs and benefits of
enhancing screening or treatment. Overall, our results sug-
gest that maximal improvements in breast cancer outcomes
could be achieved by concentrating resources on delivery of
the most intensive treatment regimens to all African Amer-
ican patients with breast cancer. Additional investments in
screening should be reserved for situations in which there
are pockets of unscreened women or for ensuring that all
high-risk women are screened.
Meta-analyses of breast cancer polydrug chemother-
apy and tamoxifen clinical trials have demonstrated statis-
tically significant reductions in overall mortality in general
populations around the world.85,86 On the basis of these
results, current standards of care for local and regional
breast cancer include recommendations for systemic treat-
ment.55,56 Currently, there is no evidence to suggest that
chemotherapy pharmacokinetics, which may differ by race,
influence treatment effectiveness.87 For instance, Dignam et
al88,89 demonstrated equal efficacy of adjuvant tamoxifen
and chemotherapy in African American and white breast
cancer patients treated in cooperative group trials. Current
patterns of treatment remain suboptimal, and nationally
only one half of African American women with breast can-
cer who are eligible for systemic adjuvant chemotherapy
are, in fact, receiving some form of systemic treatment.54
At present, we do not know the reasons for the diver-
gence of the patterns of care and guidelines for African
American women. It is possible that physicians are empha-
sizing treatment toxicity and quality of life, and not sur-
vival, or that patients are poorly informed about
chemotherapy risks and benefits. Significant comorbidity
or strong patient preferences may be very legitimate reasons
for the omission of systemic adjuvant treatment, whereas
lack of insurance, race, socioeconomic status, or incomplete
understanding should not preclude this treatment. Unfor-
tunately, there are pervasive differences in access to cancer
treatment services, including chemotherapy and referral to
a medical oncologist3 by race, income, education, or insur-
ance and setting of care.90-98 Although National Cancer
Institute cooperative group trials have enrolled numbers of
African Americans proportional to the population cancer
burden,99 African Americans are still less likely to be offered
trial participation than white patients.100
Patient beliefs may also affect patterns of care. Cancer is
a disease with strong stigma.101-103 Cancer treatments are
often perceived as “worse than the disease” and can “make
you sicker instead of better.”104 Decision making and
prognosis are often deferred to God: “If it’s my time, God
will decide” and “God directed me...to the treatments I
had.”104 After the Tuskegee Study, such ideas are com-
pounded by mistrust of the medical care system by Afri-
can American patients.105,106
Our results suggest that substantial investments could
be made in educational or other interventions to overcome
barriers to care and improve referral for and uptake of
systemic adjuvant therapy for breast cancer among African
American women. Such investments results in costs per live
years saved that are well within acceptable ranges.84 Exam-
ples of interventions that might be used to increase the
proportion of African American women receiving recom-
mended treatment include peer treatment workers (ad-
dressing trust and shared cultural perspectives), tailored
decision aides (using cultural and patient-specific tailoring
to overcome barriers), physician education (enhancing sen-
sitivity and elicitation of patient preferences), and physician
chart audit with feedback. We estimate that any of these
approaches would cost less than our threshold of approxi-
mately $6,000 per patient. However, given the complexity
of treatment delivery and decisions and patient adherence,
the optimal benefits projected in our model may not be fully
realized, even with the best interventions. Nonetheless,
given current patterns of care, any improvement in dissem-
ination of recommended treatment should be cost effective.
The fact that screening rates are high in the United
States and that rates are similar for African American and
white patients13 reflects the success of decades of screening
interventions. We evaluated the ability of the most effective
(and least costly) interventions79,80 to further improve out-
comes at the current point in time. Given the success of
prior programs, additional efforts are quite expensive rela-
tive to the additional savings in lives, unless targeted to
pockets of unscreened women or to women at twice the
average risk of disease. Thus reaching hard to reach women
who are unscreened or underscreened and educating
women about risk factors remain important goals. It is also
possible that screening results would differ with the avail-
ability of newer, more sensitive screening tests. Addition-
ally, for women destined to develop ER-positive cancer,
tamoxifen seems to be cost effective in high-risk white
women.107 It will be important to examine the balance of
risks and benefits for African American women, who have
fewer ER-positive tumors and a higher prevalence of car-
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diovascular diseases that predispose to side effects than
white women.108
Our model results are similar to other evaluations of
screening in general populations. For instance, Elmore et
al109 estimated that the cumulative risk for 40- to 49-year-
old women having a false-positive mammogram is approx-
imately 56% after 10 screens, and our model predicts a 54%
risk. Our estimate of the lifetime risk of breast cancer
(7.2%) is also similar to that calculated by Eddy21 in 1989
(approximately 6.5%).
Our analysis has several important strengths, including
use of current standards for cost-effectiveness analyses,26
evaluation of an important population subgroup, inclusion
of the best quality and least biased data, a robust model,
comparison of different cancer control strategies, and as-
sessment of uncertainty.
Despite these strengths, there are several caveats that
should be considered when interpreting our results, such as
precision in estimating the natural history of breast cancer
in African Americans, our method of evaluating mammog-
raphy effectiveness and choice of screening technology, use
of modeling, disutility of having a false-positive screen for
cancer, ability to detect small effects, and generalizability.
We have used the best data available to delineate the
natural history of breast cancer in African American
women. However, many aspects of the disease behavior
are poorly understood, and there are insufficient data at
this point in time to model other markers of disease
aggressiveness. Our model is designed to incorporate
such data as they become available.
Our results must be considered in the context of the
current controversies about the effectiveness of mammog-
raphy.110 We rely on observed stage distributions among
screened and unscreened populations to calculate screening
benefits. Our results are compatible with the view that
screening is associated with small improvements in life
expectancy. We did not evaluate the impact of new technol-
ogies that are currently under evaluation as alternative
screening approaches, such as digital mammography or
breast magnetic resonance imaging. When data are avail-
able on test characteristics of these strategies, we could
reassess the cost effectiveness of the new technologies rela-
tive to mammography or to treatment enhancement.
Ideally, large-scale randomized studies would be con-
ducted to evaluate optimal cancer control approaches in
African American women. However, because breast cancer
is a rare event, conducting trials of all possible approaches is
not feasible (or ethical). Under these circumstances, models
can be useful to combine the best data available and project
events over a sufficiently long time horizon to observe inci-
dence and mortality end points.111 To the extent that data
are of poor quality, or assumptions are incorrect, model
results can be inconclusive. However, there are reliable data
on the natural history of breast neoplasia, and our results
were robust over wide ranges of multiple parameters.
Our model does not capture the effects of distress asso-
ciated with a falsely positive screen or the disutility of having
cancer. We know of no data that measure breast cancer
utilities among African American women. However, the
transient nature of false-positives is not likely to alter con-
clusions of the analysis, and results were not sensitive to
assumptions about utilities for cancer states.
There were very small screening benefits associated
with enhanced use of mammography. It was difficult to
detect larger screening intervention effects for several rea-
sons. First, current rates of mammography use are quite
high.13 At these rates, the modest effects of a prototypical
intervention are insufficient to produce an appreciable ef-
fect on life expectancy. Second, this type of intervention has,
in part, become part of standard care that we used as a
comparator. Third, current treatment regimens for DCIS,
local, and regional disease are highly effective. Large im-
provements in survival resulting from screening occur pri-
marily in women who avoid presenting with distant disease.
Such women represent only a minority of women in popu-
lations where screening is in widespread use. Finally, the
relatively high cost-effectiveness ratio for enhanced screen-
ing compared with improving treatment is also related to
the fact that screening the entire population is very costly.
However, the benefits only accrue to the small number of
women who develop cancer but are averaged over the whole
population, yielding a small per woman benefit. In contrast,
the costs of treatment interventions are applied to a much
smaller number of women, all of whom will benefit directly.
Finally, our results are only generalizable to African
American women. We did not examine results for black
patients from other countries or for white women. Because
certain populations of white patients, such as low-income
or uninsured women in the United States, are also at risk for
poor cancer outcomes, this will be an important area for
future extensions of our model. The survival data we used
may not be representative of the general population of
African American women, because clinical trials generally
enroll healthy volunteers. However, these trials did include
a representative sample of African American women (10%
to 12%), enhancing the external validity of our results.
The results of this cost-effectiveness analysis are in-
tended to inform clinical and policy debates about cancer
services for vulnerable populations. Overall, our results
suggest that except in pockets of unscreened or high-risk
women, investments in further improvements in screening
use are unlikely to be an efficient use of limited health care
resources. The most cost-effective interventions are likely to
be those ensuring that African American women receive the
most intensive treatment once cancer is diagnosed.
  
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